Browsing by Subject "Biotherapeutic loading"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    ItemEmbargo
    Enhancing preventive and therapeutic cancer vaccine efficacy through biotherapeutic ligand-associated extracellular vesicles
    (Elsevier Ltd, 2024-12) Kahraman, Tamer; Akpınar, Gözde Güçlüler; Yıldırım, Muzaffer; Larssen, Pia; Bayyurt-Kocabaş, Banu; Yağcı, Fuat Cem; Gürsel, Arda; Horuluoğlu, Begüm Han; Yazar, Volkan; Ayanoğlu, İhsan Cihan; Yıldırım, Tuğce Canavar; Evcili, İrem; Yılmaz, İsmail Cem; Eldh, Maria; Gabrielsson, Susanne; Güler, Ülkü; Salih, Bekir; Gursel, Mayda; Gürsel, İhsan
    Extracellular vesicles (EVs), secreted by almost all living cells, have gained significant attention for their role in intercellular communication and their potential as versatile carriers for biotherapeutics. However, the clinical translation of EV-based therapies faces significant challenges, primarily due to the lack of efficient methods for loading biotherapeutic agents into EVs. This study introduces a simple, reproducible strategy for the simultaneous incorporation of various biotherapeutics within EVs. The process is gentle and preserves the essential physicochemical and biological characteristics of EVs, thereby protecting labile ligands from premature degradation and elimination. The binding and uptake efficiency of EVs by target cells reached approximately 97 % within 24 h of incubation. Administration of EVs loaded with oligodeoxynucleotides (ODN) resulted in a 4-fold increase in $IFNy^{+}$ $CD4^{+}$ T cells and a 5-fold increase in $IFNy^{+}$ $CD8^{+}$ T cells in the spleens and lymph nodes. Additionally, the co-administration of EVs with ODN and ovalbumin (OVA) induced elevated Th1-biased antibody responses and antigen-specific cytotoxic T-cell responses, providing long-lasting complete protection in 60 % of mice against T-cell thymoma challenge. Furthermore, EVs associated with three different ligands (OVA, CpG-ODN, and α-GalCer) effectively regressed established murine melanoma and significantly improved survival rates in mice. This study presents a powerful and promising approach to overcoming the limitations of EV-based cancer vaccines, advancing the development of effective cancer immunotherapies.